Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors
- PMID: 9007506
- DOI: 10.1016/s0014-2999(96)00752-2
Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors
Abstract
The antinociceptive effect of peripheral delta 9-tetrahydrocannabinol was examined in mice previously treated with an inactive dose of morphine. The ED50 of delta 9-tetrahydrocannabinol was significantly reduced by morphine, both in the tail-flick test (0.85 vs. 2.10 mg/kg) and in the hot-plate test (1.51 vs. 4.71 mg/kg and 0.73 vs. 2.47 mg/kg in jumping and paw-lick responses, respectively). The synergistic effect between morphine and delta 9-tetrahydrocannabinol was partially blocked by the cannabinoid receptor antagonist, SR-141,716 A [(N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichorophenyl)-4-methyl-3 -pyrazolecarboxamide, hydrochloride)], at a dose of 2 mg/kg (i.p.) as well as by the opioid receptor antagonist naloxone, at the dose of 1 mg/kg (s.c.). Such an effect was also blocked by i.t. nor-binaltorphimine (a kappa-selective opioid receptor antagonist) given at 20 micrograms/mouse as well as by beta-funaltrexamine (a mu-selective opioid receptor antagonist) at a dose of 2 nmol/mouse (i.c.v., 24 h before the test). Accordingly, the mu-opioid receptor agonist DAMGO ([D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin) potentiated the effect of delta 9-tetrahydrocannabinol. These data show that the synergism between morphine and delta 9-tetrahydrocannabinol appears to involve cannabinoid as well as mu-supraspinal and kappa-spinal opioid receptors.
Similar articles
-
Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.J Pharmacol Exp Ther. 2003 Dec;307(3):1135-41. doi: 10.1124/jpet.103.056242. Epub 2003 Oct 13. J Pharmacol Exp Ther. 2003. PMID: 14557378
-
Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord.J Pharmacol Exp Ther. 2004 Jul;310(1):240-6. doi: 10.1124/jpet.104.065334. Epub 2004 Mar 3. J Pharmacol Exp Ther. 2004. PMID: 14999057
-
Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.Brain Res. 2006 Apr 14;1083(1):61-9. doi: 10.1016/j.brainres.2006.01.095. Epub 2006 Mar 10. Brain Res. 2006. PMID: 16530171
-
Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence.Neurochem Res. 1996 Nov;21(11):1347-51. doi: 10.1007/BF02532375. Neurochem Res. 1996. PMID: 8947924 Review.
-
mu-Opposing actions of the kappa-opioid receptor.Trends Pharmacol Sci. 1998 Mar;19(3):94-8. doi: 10.1016/s0165-6147(98)01169-9. Trends Pharmacol Sci. 1998. PMID: 9584625 Review.
Cited by
-
Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.J Pharmacol Exp Ther. 2013 Jun;345(3):354-62. doi: 10.1124/jpet.113.204099. Epub 2013 Mar 27. J Pharmacol Exp Ther. 2013. PMID: 23536317 Free PMC article.
-
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.Neuropsychopharmacology. 2022 Jun;47(7):1315-1330. doi: 10.1038/s41386-022-01322-4. Epub 2022 Apr 22. Neuropsychopharmacology. 2022. PMID: 35459926 Free PMC article.
-
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.J Neurol. 2015 Jan;262(1):27-40. doi: 10.1007/s00415-014-7502-9. Epub 2014 Sep 30. J Neurol. 2015. PMID: 25270679 Clinical Trial.
-
Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor.Br J Pharmacol. 2009 Sep;158(1):225-31. doi: 10.1111/j.1476-5381.2009.00310.x. Epub 2009 Jul 7. Br J Pharmacol. 2009. PMID: 19594755 Free PMC article.
-
Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.Psychopharmacology (Berl). 2005 Nov;182(4):527-36. doi: 10.1007/s00213-005-0114-4. Epub 2005 Oct 19. Psychopharmacology (Berl). 2005. PMID: 16079992
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials